Annovis Bio to Present at the BIO CEO & Investor Digital Conference
February 16 2021 - 06:45AM
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug
platform company addressing Alzheimer’s disease (AD), Parkinson’s
disease (PD) and other neurodegenerative diseases, today announced
that Maria Maccecchini, Ph.D., Founder and Chief Executive Officer,
will present at the BIO CEO & Digital Conference, available
online February 16-18, 2021. Annovis Bio’s presentation will be
accessible on demand during the virtual event for all registered
attendees.
Event registration is available
at https://www.bio.org/events/bio-ceo-investor-digital-conference
About Annovis Bio
Headquartered in Berwyn, Pennsylvania, Annovis
Bio, Inc. (Annovis) is a clinical-stage, drug platform company
addressing neurodegeneration, such as Alzheimer's disease (AD),
Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS).
We believe that we are the only company developing a drug for AD,
PD and AD-DS that inhibits more than one neurotoxic protein and,
thereby, improves the information highway of the nerve cell, known
as axonal transport. When this information flow is impaired, the
nerve cell gets sick and dies. We expect our treatment to improve
memory loss and dementia associated with AD and AD-DS, as well as
body and brain function in PD. We have two ongoing Phase 2a
studies: one in AD patients and one in both AD and PD patients. For
more information on Annovis, please visit the company's
website: www.annovisbio.com.
Forward-Looking Statements
Statements in this press release contain
“forward-looking statements” that are subject to substantial risks
and uncertainties. Forward-looking statements contained in this
press release may be identified by the use of words such as
“anticipate,” “expect,” “believe,” “will,” “may,” “should,”
“estimate,” “project,” “outlook,” “forecast” or other similar
words, and include, without limitation, statements regarding the
timing, effectiveness and anticipated results of ANVS401 clinical
trials and the approval of any allowances or additional patents.
Forward-looking statements are based on Annovis Bio, Inc.’s
current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict, including the
risk that additional patent allowances may not be received.
Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
These and other risks and uncertainties are described more fully in
the section titled “Risk Factors” in the Annual Report on Form 10-K
for the year ended December 31, 2019 filed with
the Securities and Exchange Commission. Forward-looking
statements contained in this announcement are made as of this date,
and Annovis Bio, Inc. undertakes no duty to update such
information except as required under applicable law.
Investor Relations:
Dave Gentry, CEORedChip Companies
Inc.407-491-4498Dave@redchip.com
SOURCE: Annovis Bio, Inc.
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Mar 2023 to Mar 2024